Gene:
ADRB1
adrenoceptor beta 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA H1 N/A N/A N/A
No VIP available No VIP available VA H2 N/A N/A N/A
No VIP available No VIP available VA H3 N/A N/A N/A
rs1801252 115804036A>G, 145A>G, 5231A>G, 66608500A>G, ADRB1:49Ser>Gly, ADRB1:Ser49Gly, Ser49Gly
A > G
Missense
Ser49Gly
rs1801253 115805056G>C, 1165C>G, 1165G>C, 6251G>C, 66609520G>C, ADRB1:389Arg>Gly, ADRB1:Arg389Gly, Gly389Arg
G > C
Missense
Gly389Arg
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA38

Details

Cytogenetic Location: chr10 : q25.3 - q25.3
GP mRNA Boundary: chr10 : 115803806 - 115806667
GP Gene Boundary: chr10 : 115793806 - 115809667
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

The Beta1-adrenergic receptor (Beta-1-AR) is a G-protein-coupled receptor that was first characterized by its pharmacological specificity. The gene for this receptor (ADRB1) was cloned in 1987 from a placental cDNA library and subsequently mapped to chromosome 10q24-q26 (10q25.3) [Article:2825170, 2154750]. The intronless gene consists of 1,714 bp and codes for a 51.3 kDa protein consisting of 477 amino acid residues. Beta-1-ARs are the predominant Beta-AR subtype expressed in cardiac tissue, where they mediate the heart rate and contractility. Beta-1-AR expression in renal, vascular, and adipose tissues is also physiologically important.

The 145 A>G (Ser49Gly) and 1165 C>G (Arg389Gly) variants are the most common and well studied in the Beta-1-AR gene. The variant at codon 49 results in increased agonist-promoted desensitization, whereas the codon 389 polymorphism alters G-protein coupling and adenylyl cyclase activity. The impact of these polymorphisms on cardiovascular disease and drug response has been the subject of numerous investigations, which were recently reviewed in detail [Article:16120061]. Three other validated SNPs are currently documented in dbSNP, two of which have been confirmed in resequencing efforts (SeattleSNPs). Several other SNPs have been reported but not validated [Article:11102996, 10794544]. The functional consequences of these other polymorphisms are unknown.

Citation
M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417. Full text
History

Submitted by Michael A. Pacanowski, Julie A. Johnson (PEAR)

Variant Summaries rs1801252, rs1801253
Drugs
Diseases

Haplotype Overview

These haplotypes were described in [Article:21599570], composed of two variants Ser49Gly (rs1801252 A>G) and Gly389Arg (rs1801253 G>C).

Source: PharmGKB

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.
  1. Sympathetic Nerve Pathway (Neuroeffector Junction)
    Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Curated Information ?

Publications related to ADRB1: 64

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in the beta1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. American heart journal. 2014. Jeff Janina M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human molecular genetics. 2013. Ganesh Santhi K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. European journal of clinical pharmacology. 2012. Kim Kye-Min, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of the beta1-Adrenoceptor Arg389Gly Polymorphism on Heart-Rate Responses to Bisoprolol and Carvedilol in Heart-Failure Patients. Clinical pharmacology and therapeutics. 2012. Rau T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Advancing management of hypertension through pharmacogenomics. Annals of medicine. 2012. Johnson Julie A. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. Journal of cardiac failure. 2012. Talameh Jasmine A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics. 2012. Narasimhan Sneha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Common beta1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PloS one. 2012. O'Connor Christopher M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Arg389Gly beta1-adrenoceptor gene polymorphism influences the acute effects of beta-adrenoceptor blockade on contractility in the human heart. Clinical research in cardiology : official journal of the German Cardiac Society. 2011. Huntgeburth Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011. Sehrt Daniel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals. Hypertension. 2011. Johnson Andrew D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions. Clinical pharmacology and therapeutics. 2011. Johnson J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. The American journal of cardiology. 2010. Baudhuin Linnea M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenetics and genomics. 2010. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antihypertensive drugs: past, present and future. Pharmacogenomics. 2010. Johnson Julie A. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics. 2010. Filigheddu Fabiana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2010. Metra Marco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart failure clinics. 2010. Liggett Stephen B. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clinical pharmacology and therapeutics. 2008. Pacanowski M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. The pharmacogenomics journal. 2008. Aquilante C L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenetics and genomics. 2008. Kurnik Daniel, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenetics and genomics. 2008. Geese William J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure of a beta1-adrenergic G-protein-coupled receptor. Nature. 2008. Warne Tony, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and genomics. 2007. Chen Lu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. Anesthesiology. 2007. Zaugg Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism. Naunyn-Schmiedeberg's archives of pharmacology. 2007. Leineweber Kirsten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism: clinical and experimental. 2007. Lima John J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. Clinical pharmacology and therapeutics. 2007. Yu Xi-Yong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenetics and genomics. 2007. Lobmeyer Maximilian T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of the human beta-adrenergic receptors. The pharmacogenomics journal. 2007. Taylor M R G. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clinical pharmacology and therapeutics. 2006. Liu Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2006. Liggett Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Arg389Gly beta1-adrenoceptor polymorphism does not affect cardiac effects of exercise after parasympathetic inhibition by atropine. Pharmacogenetics and genomics. 2006. Leineweber Kirsten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. European journal of clinical pharmacology. 2005. Nieminen Tuomo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. The pharmacogenomics journal. 2006. Beitelshees A L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The functional significance of genetic variation within the beta-adrenoceptor. British journal of clinical pharmacology. 2005. Sandilands A J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and genomics. 2005. Terra Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clinical pharmacology and therapeutics. 2005. Terra Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and genomics. 2005. de Groote Pascal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertension research : official journal of the Japanese Society of Hypertension. 2004. Matayoshi Tetsutaro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics. 2004. La Rosée Karl, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. American journal of hypertension. 2003. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clinical pharmacology and therapeutics. 2003. Liu Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature medicine. 2003. Mialet Perez Jeanne, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology. 2003. White Hazel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes in serum lipids and antioxidant status in west Algerian patients with essential hypertension treated with acebutolol compared to healthy subjects. Medical science monitor : international medical journal of experimental and clinical research. 2003. Krouf Djamil, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical pharmacology and therapeutics. 2003. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clinical pharmacology and therapeutics. 2003. Sofowora G G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling. The Journal of biological chemistry. 2003. Rathz Deborah A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharmaceutical research. 2002. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. The New England journal of medicine. 2002. Small Kersten M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. American journal of human genetics. 2002. Ranade Koustubh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. Journal of cardiovascular electrophysiology. 2002. Kanki Hideaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. The American journal of cardiology. 2001. Humma L M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics. 2001. Xie H G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-blockade in heart failure: selective versus nonselective agents. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2001. Metra M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Novel variants in 3 kb of 5'UTR of the beta 1-adrenergic receptor gene (-93C>T, -210C>T, and -2146T>C): -2146C homozygotes present in patients with idiopathic dilated cardiomyopathy and coronary heart disease. Human mutation. 2000. Wenzel K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy?. Journal of molecular medicine (Berlin, Germany). 2000. Podlowski S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Chromosomal organization of adrenergic receptor genes. Proceedings of the National Academy of Sciences of the United States of America. 1990. Yang-Feng T L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cloning of the cDNA for the human beta 1-adrenergic receptor. Proceedings of the National Academy of Sciences of the United States of America. 1987. Frielle T, et al. PubMed

LinkOuts

Entrez Gene:
153
OMIM:
109630
607276
UCSC Genome Browser:
NM_000684
RefSeq RNA:
NM_000684
RefSeq Protein:
NP_000675
RefSeq DNA:
AC_000053
AC_000142
NC_000010
NG_012187
NT_030059
NW_001838006
NW_924884
UniProtKB:
ADRB1_HUMAN (P08588)
Ensembl:
ENSG00000043591
GenAtlas:
ADRB1
GeneCard:
ADRB1
MutDB:
ADRB1
ALFRED:
LO218647C
HuGE:
ADRB1
Comparative Toxicogenomics Database:
153
ModBase:
P08588
HumanCyc Gene:
HS00572
IUPHAR Receptor:
β1-adrenoceptor (28)
HGNC:
285

Common Searches